Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (878)	12/17/2003 11:27:58 AM
From: Jibacoa	Read Replies (1) \| Respond to of 1005

As I said before, we can't blame INGN for repeating almost the same news with somewhat different titles as long as it keeps helping the stock price, but of course the stock needs to close above 9.35 in order to draw some attention.<g> Introgen Therapeutics Announces a Patent for Its New Adenoviral Vector Technology AUSTIN, Texas, Dec 17, 2003 /PRNewswire-FirstCall via Comtex/ -- Introgen Therapeutics (Nasdaq: INGN) today announced that a patent directed to classes of adenoviral vectors has been awarded to The Board of Regents of The University of Texas System and is exclusively licensed to Introgen. These classes of adenoviral vectors are particularly important in the commercial production of adenovirus vectors, and in a number of emerging cancer and gene therapy fields, such as the use of oncolytic viruses to kill cancer cells. The patent claims of U.S. 6,630,344 broadly cover adenoviruses engineered to control tissue replication through the use of tissue specific control elements. Dr. David L. Parker, Introgen's vice president for intellectual property said, "This patent complements the issued and previously announced patent relating to INGN 007, Introgen's oncolytic virus therapy being developed in collaboration with VirRx, Inc. This new patent covers the basic enabling technology for tissue specific replication, and thus will be relevant both to those involved in the development of selectively replicating oncolytic viruses as well as the commercial production of second generation adenoviruses that are predicated on adenoviral replication in specific cell types." Adenoviruses are a widely used tool in the fields of gene therapy and vaccines. This patent provides a number of useful modifications to current adenoviral technology that will provide significant advantages in the development of adenovirus-based therapies and in the commercial scale production of adenoviruses. For example, it is often desirable to have a mechanism for programming the virus to selectively replicate in targeted cancer cells while, at the same time, delivering therapeutic 'payloads,' such as tumor cell killing genes, to the targeted tumors. Additionally, many current applications of adenovirus-based therapies, particularly oncolytic virus therapies, involve tissue specific replication of the virus. Oncolytic viruses replicate in cancer cells, which leads to a disruption ("oncolysis") of these cells and tumor regression. Furthermore, in terms of commercial scale adenovirus production, it is often important to have the ability to selectively replicate the adenoviruses in particular producer cells. This patent covers adenovirus vectors that have all of these important capabilities. bigcharts.marketwatch.com